Yahoo
Paris - Delayed Quote EUR

OSE Immunotherapeutics SA (OSE.PA)

1.8500 -0.1020 (-5.23%)
At close: 5:37:31 PM GMT+1
View in AlphaSpace Currency in EUR All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
2,619
2,619
69,877
2,227
18,302
Operating Expense
39,187
39,187
26,311
25,278
36,698
Operating Income
-36,568
-36,568
43,566
-23,051
-18,396
Net Non Operating Interest Income Expense
-2,166
-2,166
-1,835
-1,934
-1,357
Pretax Income
-37,414
-37,414
39,832
-23,221
-18,022
Tax Provision
275
275
2,387
-219
-263
Net Income Common Stockholders
-37,689
-37,689
37,445
-23,003
-17,760
Diluted NI Available to Com Stockholders
-37,689
-37,689
37,445
-23,003
-17,760
Basic EPS
-1.69
-1.69
--
-1.18
-0.96
Diluted EPS
-1.69
-1.69
--
-1.18
-0.96
Basic Average Shares
22,287.4050
22,287.4050
--
19,562.1470
18,527.4010
Diluted Average Shares
22,287.4050
22,287.4050
--
19,562.1470
18,527.4010
Total Operating Income as Reported
-37,486
-37,486
43,735
-22,986
-18,476
Total Expenses
39,187
39,187
26,311
25,278
36,698
Net Income from Continuing & Discontinued Operation
-37,689
-37,689
37,445
-23,003
-17,760
Normalized Income
-38,669.2500
-38,669.2500
39,214.2180
-24,787.0146
-19,468.6953
Interest Income
789
789
1,467
335
15
Interest Expense
2,821
2,821
3,172
2,195
1,372
Net Interest Income
-2,166
-2,166
-1,835
-1,934
-1,357
EBIT
-34,593
-34,593
43,004
-21,026
-16,650
EBITDA
-31,345
-31,345
46,314
-17,501
-13,113
Reconciled Depreciation
3,248
3,248
3,310
3,525
3,537
Net Income from Continuing Operation Net Minority Interest
-37,689
-37,689
37,445
-23,003
-17,760
Total Unusual Items Excluding Goodwill
1,307
1,307
-1,882
1,801
1,734
Total Unusual Items
1,307
1,307
-1,882
1,801
1,734
Normalized EBITDA
-32,652
-32,652
48,196
-19,302
-14,847
Tax Rate for Calcs
0.0003
0.0003
0.0001
0
0
Tax Effect of Unusual Items
326.7500
326.7500
-112.7820
16.9854
25.3047
12/31/2022 - 3/30/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: